Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Actuate Therapeutics IncNASDAQ: ACTU

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
ACTU Competitors
Cost of Revenue for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$29.7M USD-64.0%—161.2%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
NKTXNkarta, Inc.LTM Mar 2026$2.34M USD———
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026$1.39M USD-86.2%—120.9%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
VORVor Biopharma Inc.LTM Mar 2026$28K USD-98.4%——
ACTUActuate Therapeutics IncLTM Mar 2026$0 USD———
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding ACTU) —-86.2%-30.4%120.9%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.